Match!

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma

Published on Mar 2, 2018in Frontiers in Immunology4.716
· DOI :10.3389/fimmu.2018.00411
Jessica Duarte4
Estimated H-index: 4
(Ludwig Institute for Cancer Research),
Sagun Parakh9
Estimated H-index: 9
(Ludwig Institute for Cancer Research)
+ 7 AuthorsJonathan Cebon61
Estimated H-index: 61
(Ludwig Institute for Cancer Research)
Abstract
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced melanoma. The first ICI to demonstrate clinical benefit, ipilimumab, targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), however long-term overall survival is just 22%. More than 40 years ago intralesional Bacillus Calmette-Guerin (BCG), a living attenuated strain of Mycobacterium bovis, was found to induce tumor regression by stimulating cell-mediated immunity following a localized and self-limiting infection. We evaluated these two immune stimulants in combination in melanoma with the aim of developing a more effective immunotherapy and to assess toxicity. In this phase I study patients with histologically confirmed stage III/IV metastatic melanoma received intralesional BCG injection followed by up to four cycles of intravenous ipilimumab (anti-CTLA-4) (ClinicalTrials.gov number NCT01838200). The trial was discontinued following treatment of the first five patients as the two patients receiving the escalation dose of BCG developed high-grade immune–related adverse events (irAEs) typical of ipilimumab monotherapy. These irAEs were characterized in both patients by profound increases in the repertoire of autoantibodies directed against both self- and cancer-antigens. Interestingly, the induced autoantibodies were detected at time points that preceded the development of symptomatic toxicity. There was no overlap in the antigen specificity between patients, and no evidence of clinical responses. Efforts to increase response rates through the use of novel immunotherapeutic combinations may be associated with higher rates of irAEs, thus the imperative to identify biomarkers of toxicity remains strong. While the small patient numbers in this trial do not allow for any conclusive evidence of predictive biomarkers, the observed changes warrant further examination of autoantibody repertoires in larger patient cohorts at risk of developing irAEs during their course of treatment. In summary: Dose escalation of intralesional BCG followed by ipilimumab therapy was not well tolerated in advanced melanoma patients and showed no evidence of clinical benefit. Measuring autoantibody responses may provide an early means for identifying patients at risk from developing severe irAEs during cancer immunotherapy.
  • References (40)
  • Citations (10)
📖 Papers frequently viewed together
42 Citations
36 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References40
Newest
#1Antoni Ribas (UCLA: University of California, Los Angeles)H-Index: 100
#2Reinhard DummerH-Index: 98
Last. Georgina V. Long (USYD: University of Sydney)H-Index: 73
view all 20 authors...
Summary Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurr...
279 CitationsSource
#1Mark Ayers (MSD: Merck & Co.)H-Index: 13
#2Jared Lunceford (MSD: Merck & Co.)H-Index: 23
Last. Terrill K. McClanahan (MSD: Merck & Co.)H-Index: 52
view all 15 authors...
Abstract Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant...
351 CitationsSource
#1Jessica Duarte (La Trobe University)H-Index: 4
#2Jonathan M. Blackburn (UCT: University of Cape Town)H-Index: 22
ABSTRACTIntroduction: High-content protein microarrays in principle enable the functional interrogation of the human proteome in a broad range of applications, including biomarker discovery, profiling of immune responses, identification of enzyme substrates, and quantifying protein-small molecule, protein-protein and protein-DNA/RNA interactions. As with other microarrays, the underlying proteomic platforms are under active technological development and a range of different protein microarrays a...
16 CitationsSource
#1Carl H. JuneH-Index: 124
Last. Jeffrey A. BluestoneH-Index: 137
view all 3 authors...
In this Perspective, June, Bluestone and Warshauer discuss potential cellular and molecular explanations for the autoimmunity often associated with immunotherapy, and propose additional research and changes to reporting practices to aid efforts to understand and minimize these toxic side effects.
98 CitationsSource
#1Jason J. LukeH-Index: 27
#2Keith T. FlahertyH-Index: 93
Last. Georgina V. LongH-Index: 73
view all 4 authors...
In less than a decade, the treatment landscape of metastatic melanoma has changed dramatically. Novel targeted agents and immunotherapies are revolutionizing patient outcomes, but the range of available drugs complicates clinical decision-making. Herein, the authors chart the therapeutic advances and review the current evidence that can be used to guide therapeutic decisions for individual patients with metastatic melanoma, highlighting knowledge gaps.
223 CitationsSource
#1Geoffrey T. Gibney (MedStar Georgetown University Hospital)H-Index: 22
#2Louis M Weiner (MedStar Georgetown University Hospital)H-Index: 1
Last. Michael B. Atkins (MedStar Georgetown University Hospital)H-Index: 40
view all 3 authors...
Summary The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination ap...
270 CitationsSource
#1Pauline Zaenker (ECU: Edith Cowan University)H-Index: 3
#2Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
Last. Melanie ZimanH-Index: 24
view all 3 authors...
A link between autoimmune responses and cancer via autoantibodies was first described in the 1950s. Since, autoantibodies have been studied for their potential use as cancer biomarkers, however the exact causes of their production remain to be elucidated. This review summarizes current theories of the causes of autoantibody production in cancer, namely: 1) defects in tolerance and inflammation, 2) changes in protein expression levels, 3) altered protein structure, and 4) cellular death mechanism...
46 CitationsSource
#1Suzanne L. TopalianH-Index: 82
#2Janis M. TaubeH-Index: 41
Last. Drew M. PardollH-Index: 116
view all 4 authors...
This Review assesses the mechanism-based biomarkers in use and in development for immune checkpoint inhibition, identifying cancer types and cancer phenotypes that are most likely to respond to immune checkpoint blockade, and considerations for future biomarkers of immune checkpoint response.
616 CitationsSource
#2Ai Huey TanH-Index: 8
Last. Jamuna VadiveluH-Index: 25
view all 9 authors...
Parkinson's disease (PD) is the second most common chronic and progressive neurodegenerative disorder. Its etiology remains elusive and at present only symptomatic treatments exists. Helicobacter pylori chronically colonizes the gastric mucosa of more than half of the global human population. Interestingly, H. pylori positivity has been found to be associated with greater of PD motor severity. In order to investigate the underlying cause of this association, the Sengenics Immunome protein array,...
11 CitationsSource
#1Willy Hugo (UCLA: University of California, Los Angeles)H-Index: 19
#2Jesse M. Zaretsky (UCLA: University of California, Los Angeles)H-Index: 11
Last. Roger S. LoH-Index: 45
view all 18 authors...
PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy. We find that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2. Innately resistant tumors display a transcriptional sig...
696 CitationsSource
Cited By10
Newest
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Marco Iafolla (UHN: University Health Network)
Last. Anna Spreafico (UHN: University Health Network)H-Index: 13
view all 13 authors...
Background: Validated biomarkers are needed to identify patients at increased risk of immune-related adverse events (irAEs) to immune checkpoint blockade (ICB). Antibodies directed against endogenous antigens can change after exposure to ICB. Methods: Patients with different solid tumors stratified into cohorts received pembrolizumab every 3 weeks in a Phase II trial (INSPIRE study). Blood samples were collected prior to first pembrolizumab exposure (baseline) and approximately 7 weeks (pre-cycl...
Source
#1Patrick J. Boland (NYU: New York University)H-Index: 1
#2Anna C. Pavlick (NYU: New York University)H-Index: 44
view all 4 authors...
In the past 10 years, immune checkpoint inhibitors (ICIs) have become an additional pillar of cancer therapy by activating the immune system to treat a number of different malignancies. Many patients receiving ICIs develop immune-related adverse events (irAEs) that mimic some features of classical autoimmune diseases. Unfortunately, patients with underlying autoimmune conditions, many of whom have an increased risk for malignancy, have been excluded from clinical trials of ICIs due to a concern ...
Source
#1Pascal UrwylerH-Index: 1
#2Irina Earnshaw ('KCL': King's College London)H-Index: 1
Last. Nick Powell ('KCL': King's College London)H-Index: 20
view all 12 authors...
Immune checkpoint inhibition has revolutionized the treatment of several solid cancers, most notably melanoma and non-small-cell lung cancer (NSCLC). Drugs targeting cytotoxic T lymphocyte antigen (CTLA)-4 and programmed cell death 1 (PD-1) have made their way into routine clinical use; however, this has not been without difficulties. Stimulation of the immune system to target cancer has been found to result in a reduction of self-tolerance, leading to the development of adverse effects that res...
2 CitationsSource
#1Dennis McGonagle (Chapel Allerton Hospital)H-Index: 70
#2Nicola Luigi Bragazzi (Sheba Medical Center)H-Index: 1
Last. Abdulla Watad (UniGe: University of Genoa)H-Index: 3
view all 4 authors...
Abstract Improved anti-tumour responses under immune checkpoint inhibition (ICI) are associated with concomitant autoimmune disease development termed immune related adverse events (irAEs), of which approximately 5% are rheumatic in nature. Generally, oncologists and other specialists vigorously treat irAEs in spite of the generally accepted beneficial effect of irAEs on tumour survival. Herein, we highlight mechanistic insights on how tumour responses and certain types of autoimmunity appear to...
Source
#1Jan Leipe (LMU: Ludwig Maximilian University of Munich)H-Index: 12
#2Xavier Mariette (University of Paris-Sud)H-Index: 81
Since immune checkpoint inhibitors became the standard of care for an increasing number of indications, more patients have been exposed to these drugs and physicians are more challenged with the management of a unique spectrum of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors. Those irAEs of autoimmune or autoinflammatory origin, or both, can involve any organ or tissue, but most commonly affect the dermatological, gastrointestinal and endocrine systems. Rheum...
4 CitationsSource
#1Salahaldin A. Tahir (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Jianjun Gao (University of Texas MD Anderson Cancer Center)H-Index: 16
Last. Padmanee Sharma (University of Texas MD Anderson Cancer Center)H-Index: 48
view all 12 authors...
Immune checkpoint (IC) therapy provides substantial benefits to cancer patients but can also cause distinctive toxicities termed immune-related adverse events (irAEs). Biomarkers to predict toxicities will be necessary to improve management of patients receiving IC therapy. We relied on serological analysis of recombinant cDNA expression libraries to evaluate plasma samples from patients treated with IC therapy and identified autoantibodies, both in pretreatment and on-treatment samples prior to...
4 CitationsSource
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Antoninus Soosaipillai (MSH: Mount Sinai Hospital, Toronto)H-Index: 35
Last. Eleftherios P. DiamandisH-Index: 99
view all 6 authors...
Background Autoantibodies are produced when tolerance to self-antigens is broken and they can be mediators of tissue injury and systemic inflammation. They are excellent biomarkers because they are minimally invasive to screen and are highly abundant in serum due to limited proteolysis and slow clearance. Conventionally used methods of identifying autoantibodies in patient sera include indirect immunofluorescence, enzyme-linked immunoabsorbent assays (ELISAs) and protein microarrays. Here we pre...
1 CitationsSource
#1Rachel Tanner (University of Oxford)H-Index: 13
#2Bernardo Villarreal-Ramos (Aberystwyth University)H-Index: 26
Last. Helen McShane (University of Oxford)H-Index: 47
view all 4 authors...
Bacillus Calmette Guerin (BCG) is the only currently available vaccine against tuberculosis (TB), but it confers incomplete and variable protection against pulmonary TB in humans and bovine TB (bTB) in cattle. Insights into the immune response induced by BCG offer an underexploited opportunity to gain knowledge that may inform the design of a more efficacious vaccine, which is urgently needed to control these major global epidemics. Humoral immunity in TB and bTB has been neglected, but recent s...
1 CitationsSource
In the last decade, inhibitors targeting immune checkpoint molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) brought about a major paradigm shift in cancer treatment. These immune checkpoint inhibitors (ICIs) improved the overall survival of a variety of cancer such as malignant melanoma and non-small lung cancer. In addition, numerous clinical trials for additional indication of ICIs including adjuvant and neo-...
2 CitationsSource
#1Anne LargeotH-Index: 3
#2Giulia PaganoH-Index: 1
Last. Jerome PaggettiH-Index: 15
view all 5 authors...
Tumor-infiltrating lymphocytes are known to be critical in controlling tumor progression. While the role of T lymphocytes has been extensively studied, the function of B cells in this context is still ill-defined. In this review, we propose to explore the role of B cells in tumor immunity. First of all we define their dual role in promoting and inhibiting cancer progression depending on their phenotype. To continue, we describe the influence of different tumor microenvironment factors such as hy...
1 CitationsSource